补充左旋肉碱对糖耐量受损和糖尿病参与者心血管危险因素的影响：一项系统评价和剂量反应荟萃分析。

The effects of L-carnitine supplementation on cardiovascular risk factors in participants with impaired glucose tolerance and diabetes: a systematic review and dose-response meta-analysis.

作者信息

Gheysari Rezvan, Nikbaf-Shandiz Mahlagha, Hosseini Amir Mehdi, Rasaei Niloufar, Hosseini Shabnam, Bahari Hossein, Asbaghi Omid, Rastgoo Samira, Goudarzi Kian, Shiraseb Farideh, Behmadi Reza

机构信息

Shohada-E-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

出版信息

Diabetol Metab Syndr. 2024 Jul 31;16(1):185. doi: 10.1186/s13098-024-01415-8.

AIMS

L-carnitine plays a role related to cardiometabolic factors, but its effectiveness and safety in CVD are still unknown. We aim to assess the effect of L-carnitine supplementation on CVD risk factors.

METHODS

A systematic literature search was conducted in PubMed, Web of Science, and Scopus until October 2022. The main outcomes were lipid profiles, anthropometric parameters, insulin resistance, serum glucose levels, leptin, blood pressure, and inflammatory markers. The pooled weighted mean difference (WMD) was calculated using a random-effects model.

RESULTS

We included the 21 RCTs (n = 2900) with 21 effect sizes in this study. L-carnitine supplementation had a significant effect on TG (WMD = - 13.50 mg/dl, p = 0.039), LDL (WMD = - 12.66 mg/dl, p < 0.001), FBG (WMD = - 6.24 mg/dl, p = 0.001), HbA1c (WMD = -0.37%, p = 0.013) HOMA-IR (WMD = -0.72, p = 0.038 (, CRP (WMD = - 0.07 mg/dl, P = 0.037), TNF-α (WMD = - 1.39 pg/ml, p = 0.033), weight (WMD = - 1.58 kg, p = 0.001 (, BMI (WMD = - 0.28 kg/m, p = 0.017(, BFP (WMD = - 1.83, p < 0.001) and leptin (WMD = - 2.21 ng/ml, p = 0.003 (in intervention, compared to the placebo group, in the pooled analysis.

CONCLUSIONS

This meta-analysis demonstrated that administration of L-carnitine in diabetic and glucose intolerance patients can significantly reduce TG, LDL-C, FBG, HbA1c, HOMA-IR, CRP, TNF-α, weight, BMI, BFP, and leptin levels. PROSPERO registration code: CRD42022366992.

目的

左旋肉碱与心脏代谢因素有关，但其在心血管疾病（CVD）中的有效性和安全性尚不清楚。我们旨在评估补充左旋肉碱对心血管疾病危险因素的影响。

方法

截至2022年10月，在PubMed、科学网和Scopus中进行了系统的文献检索。主要结局指标为血脂谱、人体测量参数、胰岛素抵抗、血清葡萄糖水平、瘦素、血压和炎症标志物。采用随机效应模型计算合并加权平均差（WMD）。

结果

本研究纳入了21项随机对照试验（RCTs，n = 2900），有21个效应量。在汇总分析中，与安慰剂组相比，补充左旋肉碱对甘油三酯（WMD = - 13.50 mg/dl，p = 0.039）、低密度脂蛋白（WMD = - 12.66 mg/dl，p < 0.001）、空腹血糖（WMD = - 6.24 mg/dl，p = 0.001）、糖化血红蛋白（WMD = -0.37%，p = 0.013）、稳态模型评估的胰岛素抵抗指数（HOMA-IR，WMD = -0.72，p = 0.038）、C反应蛋白（CRP，WMD = - 0.07 mg/dl，P = 0.037）、肿瘤坏死因子-α（TNF-α，WMD = - 1.39 pg/ml，p = 0.033）、体重（WMD = - 1.58 kg，p = 0.001）、体重指数（BMI，WMD = - 0.28 kg/m²，p = 0.017）、体脂百分比（BFP，WMD = - 1.83，p < 0.001）和瘦素（WMD = - 2.21 ng/ml，p = 0.003）有显著影响。